Neuromodulation With Percutaneous Electrical Nerve Field Stimulation

Inclusion Criteria: * Ability to provide written, informed consent * Patients who meet Rome IV criteria for Functional Dyspepsia (FD), with or without a delay in gastric emptying: * One or more of the following: Bothersome postprandial fullness, Bothersome early satiation, Bothersome epigastric pain, Bothersome epigastric burning * No evidence of structural disease that is likely to explain the symptoms * Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis * Average daily worst abdominal pain score between 4 and 8 (on a 0-10-point rating scale) during the screening period. A minimum reporting of abdominal pain will be required for 5/7 days in the baseline period. * Minimum of 2 days of abdominal pain/week prior to starting trial. * At least moderate symptom severity with a GCSI score of at least 2.0 during screening * If receiving pharmacologic therapy for abdominal pain associated with GPLS, doses must be stable for at least 60 days prior to randomization. * If receiving pharmacologic therapy for GPLS that does not have an effect on abdominal pain, doses must be stable for at least 30 days prior to randomization. Exclusion Criteria: * Patients under the age of 18 years or over the age of 60 years * Patients who cannot provide informed consent or do not speak English * Co-morbid, organic medical conditions associated with abdominal pain, including: Inflammatory bowel disease, chronic liver disease, peptic ulcer disease, celiac disease, diverticulitis, appendicitis, colorectal cancer, endometriosis, pregnancy, other intestinal or extra-intestinal malignancies. Patients with overlapping functional GI disorders (i.e. IBS) will not be excluded as long as GPLS is their predominant disorder * Patients prescribed GLP-1s * History of surgery involving Cranial Nerves V, VII, IX, or X. * History of abdominal surgeries other than appendectomy or cholecystectomy at least 6 months before the screening visit. * Patients with chronic opioid, benzodiazepine, or illicit substance use within the last 6 months. * Patients with underlying neurologic conditions, including history of: seizures, CVA, uncontrolled migraines, traumatic brain injury, multiple sclerosis * Patients with severe, uncontrolled psychiatric conditions, including severe major depression, psychosis, dissociative episodes, etc. * Patients with dermatologic conditions affecting the ear, face, or neck region (i.e. psoriasis), or with cuts or abrasions to the external ear that would interfere with needle placement * Patients with hemophilia or other bleeding disorders * Patients with any implanted electrical device * Patients who are known to be pregnant or breastfeeding